中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2015年
11期
65-68
,共4页
泰素%三维适形放疗%非小细胞肺癌%老年
泰素%三維適形放療%非小細胞肺癌%老年
태소%삼유괄형방료%비소세포폐암%노년
Paclitaxel%Three-dimensional conformal radiotherapy%NSCLC%Elderly
目的：观察泰素(紫杉醇)单药联合三维适形放疗同步治疗老年晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法选择2011年6月~2013年6月我院收治的51例70~82岁的老年晚期NSCLC患者，随机分为同步放化疗组(同步组，26例)和单纯化疗组(单化组，25例)。单化组采用单药泰素化疗，应用周剂量泰素60 mg/m2，1次/周，连用3周，休息1周后继续下1个疗程，同步组在此基础上接受三维适形放疗(1.8~2.0)Gy/次/d，5次/周，总照射剂量60~66 Gy。评价和分析治疗结束后两周两组的临床疗效和不良反应。结果同步组治疗总有效率和临床获益率分别为84.6%和96.2%，均明显高于单化组的60.0%、84.0%(P<0.05)。两组的1年总生存率分别为79.2%、61.5%(P<0.05)，两组的1年无进展生存率分别为67.4%、40.0%(P<0.05)。主要的不良反应为轻度胃肠道反应、放射性食管炎和Ⅰ~Ⅲ度骨髓抑制。结论泰素单药联合同步三维适形放疗治疗老年晚期NSCLC疗效较好，不良反应轻，毒副反应能耐受。
目的：觀察泰素(紫杉醇)單藥聯閤三維適形放療同步治療老年晚期非小細胞肺癌(NSCLC)的療效和不良反應。方法選擇2011年6月~2013年6月我院收治的51例70~82歲的老年晚期NSCLC患者，隨機分為同步放化療組(同步組，26例)和單純化療組(單化組，25例)。單化組採用單藥泰素化療，應用週劑量泰素60 mg/m2，1次/週，連用3週，休息1週後繼續下1箇療程，同步組在此基礎上接受三維適形放療(1.8~2.0)Gy/次/d，5次/週，總照射劑量60~66 Gy。評價和分析治療結束後兩週兩組的臨床療效和不良反應。結果同步組治療總有效率和臨床穫益率分彆為84.6%和96.2%，均明顯高于單化組的60.0%、84.0%(P<0.05)。兩組的1年總生存率分彆為79.2%、61.5%(P<0.05)，兩組的1年無進展生存率分彆為67.4%、40.0%(P<0.05)。主要的不良反應為輕度胃腸道反應、放射性食管炎和Ⅰ~Ⅲ度骨髓抑製。結論泰素單藥聯閤同步三維適形放療治療老年晚期NSCLC療效較好，不良反應輕，毒副反應能耐受。
목적：관찰태소(자삼순)단약연합삼유괄형방료동보치료노년만기비소세포폐암(NSCLC)적료효화불량반응。방법선택2011년6월~2013년6월아원수치적51례70~82세적노년만기NSCLC환자，수궤분위동보방화료조(동보조，26례)화단순화료조(단화조，25례)。단화조채용단약태소화료，응용주제량태소60 mg/m2，1차/주，련용3주，휴식1주후계속하1개료정，동보조재차기출상접수삼유괄형방료(1.8~2.0)Gy/차/d，5차/주，총조사제량60~66 Gy。평개화분석치료결속후량주량조적림상료효화불량반응。결과동보조치료총유효솔화림상획익솔분별위84.6%화96.2%，균명현고우단화조적60.0%、84.0%(P<0.05)。량조적1년총생존솔분별위79.2%、61.5%(P<0.05)，량조적1년무진전생존솔분별위67.4%、40.0%(P<0.05)。주요적불량반응위경도위장도반응、방사성식관염화Ⅰ~Ⅲ도골수억제。결론태소단약연합동보삼유괄형방료치료노년만기NSCLC료효교호，불량반응경，독부반응능내수。
Objective To investigate the clinical efficacy of paclitaxel combined with three-dimensional conformal ra-diotherapy(3DCRT) for advanced non-small cell lung cancer(NSCLC) in the elderly. Methods From June 2011 to June 2013, 51 elderly patients with NSCLC were randomly divided into chemoradiotherapy group (n=26) and chemotherapy group(n=25). All patients were treated with weekly 60 mg/m2 of paclitaxel intravenously for 3 weeks, and patients in the chemoradiotherapy group were also treated with three-dimensional conformal radiation (1.8~2.0 Gy per fraction, 5 times per week, total dose of 60~66 Gy). The clinical efficacy and adverse reactions were compared between two groups. Re-sults In chemoradiotherapy group, the response rate was 84.6% and the overall efficiency rate was 96.2%, which were higher than 60.0% and 84.0% in chemotherapy group (P<0.05). In chemoradiotherapy group, the one year survival rate was 79.2%, which was higher than 61.5% in chemotherapy group (P<0.05), so did one year progression free survival rates (67.4% vs 40.0%)(P<0.05). The main side effects were gastrointestinal toxicity, radiation esophagitis and bone-marrow suppression. Conclusion Paclitaxel combined with three-dimensional conformal radiotherapy for advanced NSCLC in the elderly are safe and effective, the toxicity is tolerable.
